Celldex Therapeutics, Inc. (CLDX) Stock Grade

About Celldex Therapeutics, Inc.'s fundamentals

Celldex Therapeutics is a biotechnology company with a market capitalization of $1.8 billion that reported a significant net loss in its latest annual statement, resulting in a net margin of -17253.3%. The company experienced a steep 78.6% year-over-year decline in revenue, indicating a contraction in its commercial operations. With no dividend yield and negative profitability metrics, the company's financials reflect the typical cash-burn profile of a development-stage biotech firm focused on research and development rather than near-term earnings.